These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24341330)

  • 1. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials.
    Berhan A; Barker A
    BMC Endocr Disord; 2013 Dec; 13():58. PubMed ID: 24341330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials.
    Yang Y; Chen S; Pan H; Zou Y; Wang B; Wang G; Zhu H
    Medicine (Baltimore); 2017 May; 96(21):e6944. PubMed ID: 28538386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Yang L; Zhang L; He H; Zhang M; An Z
    Diabetes Ther; 2019 Oct; 10(5):1921-1934. PubMed ID: 31376072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
    Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
    Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
    Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
    Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis.
    Jingfan Z; Ling L; Cong L; Ping L; Yu C
    Arch Endocrinol Metab; 2019; 63(5):478-486. PubMed ID: 31271575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis.
    Guo M; Gu J; Teng F; Chen J; Ma X; Chen Q; Pu Y; Jiang Z; Long Y; Xu Y
    Endocrine; 2020 Feb; 67(2):294-304. PubMed ID: 31900793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients.
    Wang Y; Hu X; Liu X; Wang Z
    Ther Clin Risk Manag; 2016; 12():1113-31. PubMed ID: 27486328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Li K; Xu G
    J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
    Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
    Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes.
    Yang Y; Zhao C; Ye Y; Yu M; Qu X
    Front Endocrinol (Lausanne); 2020; 11():190. PubMed ID: 32351447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis.
    Li J; Shao YH; Wang XG; Gong Y; Li C; Lu Y
    Endocr J; 2018 Mar; 65(3):335-344. PubMed ID: 29375082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.